Bristol-Myers vet Douglas Manion bids Big Pharma farewell, takes the helm at Yale spinout Kleo
A 12-year veteran of Bristol-Myers Squibb’s R&D group is joining the migration of research execs out of Big Pharma and into up-and-coming biotech.
Douglas Manion is hanging up his spurs as head of specialty development for BMS and taking over as CEO of an upstart named Kleo Pharmaceuticals, which is pursuing new drugs spotlighted in the lab of Yale’s David Spiegel. Kleo’s focus is on small molecules that can do the job a wave of biologics have been doing in spurring an immune system attack.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.